| Epigenetics in multiple myeloma: From mechanisms to therapy M Alzrigat, AA Párraga, H Jernberg-Wiklund Seminars in cancer biology 51, 101-115, 2018 | 92 | 2018 |
| PML promotes MHC class II gene expression by stabilizing the class II transactivator T Ulbricht, M Alzrigat, A Horch, N Reuter, A von Mikecz, V Steimle, ... The Journal of cell biology 199 (1), 49, 2012 | 74 | 2012 |
| Genome-wide profiling of histone H3 lysine 27 and lysine 4 trimethylation in multiple myeloma reveals the importance of Polycomb gene targeting and highlights EZH2 as a … P Agarwal, M Alzrigat, AA Párraga, S Enroth, U Singh, J Ungerstedt, ... Oncotarget 7 (6), 6809, 2016 | 71 | 2016 |
| EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions M Alzrigat, AA Párraga, P Agarwal, H Zureigat, A Österborg, H Nahi, A Ma, ... Oncotarget 8 (6), 10213, 2017 | 62 | 2017 |
| The polycomb group protein BMI-1 inhibitor PTC-209 is a potent anti-myeloma agent alone or in combination with epigenetic inhibitors targeting EZH2 and the BET bromodomains M Alzrigat, AA Párraga, MM Majumder, A Ma, J Jin, A Österborg, H Nahi, ... Oncotarget 8 (61), 103731, 2017 | 26 | 2017 |
| Targeting EZH2 in multiple myeloma—multifaceted anti-tumor activity M Alzrigat, H Jernberg-Wiklund, JD Licht Epigenomes 2 (3), 16, 2018 | 23 | 2018 |
| The miR-125a and miR-320c are potential tumor suppressor microRNAs epigenetically silenced by the polycomb repressive complex 2 in multiple myeloma M Alzrigat, H Jernberg-Wiklund RNA & Disease (Houston, Tex.) 4 (2), 2017 | 21 | 2017 |
| MYC Inhibition Halts Metastatic Breast Cancer Progression by Blocking Growth, Invasion, and Seeding D Massó-Vallés, ME Beaulieu, T Jauset, F Giuntini, MF Zacarías-Fluck, ... Cancer Research Communications 2 (2), 110–130, 2022 | 18 | 2022 |
| HIF-1 stabilization in T cells hampers the control of Mycobacterium tuberculosis infection R Liu, V Muliadi, W Mou, H Li, J Yuan, J Holmberg, BJ Chambers, N Ullah, ... nature communications 13 (1), 5093, 2022 | 16 | 2022 |
| Pharmacological inactivation of CDK2 inhibits MYC/BCL-XL-driven leukemia in vivo through induction of cellular senescence W Bazzar, M Bocci, E Hejll, V Högqvist Tabor, P Hydbring, A Grandien, ... Cell Cycle 20 (1), 23-38, 2021 | 12 | 2021 |
| MYCMI-7: a small MYC-binding compound that inhibits MYC: MAX interaction and tumor growth in a MYC-dependent manner A Castell, Q Yan, K Fawkner, W Bazzar, F Zhang, M Wickström, M Alzrigat, ... Cancer Research Communications 2 (3), 182-201, 2022 | 10 | 2022 |
| Methods to study myc-regulated Cellular Senescence: an update F Zhang, W Bazzar, M Alzrigat, LG Larsson The Myc Gene: Methods and Protocols, 241-254, 2021 | 6 | 2021 |
| MYCN amplification is associated with reduced expression of genes encoding γ-secretase complex and NOTCH signaling components in neuroblastoma P Agarwal, A Glowacka, L Mahmoud, W Bazzar, LG Larsson, M Alzrigat International Journal of Molecular Sciences 24 (9), 8141, 2023 | 3 | 2023 |
| Target Genes of c-MYC and MYCN with Prognostic Power in Neuroblastoma Exhibit Different Expressions during Sympathoadrenal Development Y Yuan, M Alzrigat, A Rodriguez-Garcia, X Wang, TS Bexelius, JI Johnsen, ... Cancers 15 (18), 4599, 2023 | 1 | 2023 |
| Targeted Epigenetic Therapy: EZH2 Inhibition in B-cell Malignancies M Alzrigat EC Proteomics and Bioinformatics ECO 1, 07-10, 2017 | | 2017 |
| Targeted Inhibition of Polycomb Repressive Complexes in Multiple Myeloma: Implications for Biology and Therapy M Alzrigat Acta Universitatis Upsaliensis, 2017 | | 2017 |
| IKKα contains two conserved LXXLL co-activator motifs and is recruited to the retinoic acid receptor A Kalushkova, H Göransson Kultima, F Zhang, M Alzrigat, P Agarwal, ... | | 2013 |
| The role of the inhibitor of B kinase alpha (IKK) in epigenetic changes mediated by RAR-RXR nuclear receptor-activated transcription M Alzrigat | | |
